ACRS vs. PHAT, RLAY, ABUS, TNGX, CDXC, DNTH, MENS, MGTX, UPB, and XNCR
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Phathom Pharmaceuticals (PHAT), Relay Therapeutics (RLAY), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX), ChromaDex (CDXC), Dianthus Therapeutics (DNTH), Jyong Biotech (MENS), MeiraGTx (MGTX), Upstream Bio (UPB), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.
Aclaris Therapeutics vs. Its Competitors
Aclaris Therapeutics (NASDAQ:ACRS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.
Aclaris Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Phathom Pharmaceuticals has a net margin of -422.42% compared to Aclaris Therapeutics' net margin of -732.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.
In the previous week, Aclaris Therapeutics had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 1 mentions for Phathom Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.77 beat Phathom Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.
Aclaris Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aclaris Therapeutics currently has a consensus price target of $8.71, suggesting a potential upside of 449.80%. Phathom Pharmaceuticals has a consensus price target of $17.50, suggesting a potential upside of 80.52%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aclaris Therapeutics is more favorable than Phathom Pharmaceuticals.
Summary
Aclaris Therapeutics beats Phathom Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ACRS) was last updated on 7/10/2025 by MarketBeat.com Staff
Free ACRS Stock Alerts